CN106414434B - 异噻唑衍生物作为用于治疗ii型糖尿病的gpr120激动剂 - Google Patents

异噻唑衍生物作为用于治疗ii型糖尿病的gpr120激动剂 Download PDF

Info

Publication number
CN106414434B
CN106414434B CN201480078670.3A CN201480078670A CN106414434B CN 106414434 B CN106414434 B CN 106414434B CN 201480078670 A CN201480078670 A CN 201480078670A CN 106414434 B CN106414434 B CN 106414434B
Authority
CN
China
Prior art keywords
methoxy
compound
trifluoromethyl
thiazol
isothiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480078670.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN106414434A (zh
Inventor
C.R.伊里格
M.R.普拉耶
张旭庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN106414434A publication Critical patent/CN106414434A/zh
Application granted granted Critical
Publication of CN106414434B publication Critical patent/CN106414434B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201480078670.3A 2014-03-07 2014-03-07 异噻唑衍生物作为用于治疗ii型糖尿病的gpr120激动剂 Expired - Fee Related CN106414434B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/021775 WO2015134039A1 (en) 2014-03-07 2014-03-07 Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes

Publications (2)

Publication Number Publication Date
CN106414434A CN106414434A (zh) 2017-02-15
CN106414434B true CN106414434B (zh) 2019-12-31

Family

ID=50391464

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480078670.3A Expired - Fee Related CN106414434B (zh) 2014-03-07 2014-03-07 异噻唑衍生物作为用于治疗ii型糖尿病的gpr120激动剂

Country Status (8)

Country Link
EP (2) EP3114123B1 (https=)
JP (1) JP6303031B2 (https=)
CN (1) CN106414434B (https=)
AU (1) AU2014385276B2 (https=)
CA (1) CA2941445A1 (https=)
ES (2) ES2887011T3 (https=)
MX (1) MX367852B (https=)
WO (1) WO2015134039A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2944572T3 (es) 2016-03-15 2023-06-22 Univ London Queen Mary Procedimiento de tratamiento de la obesidad
JP6809278B2 (ja) * 2017-02-17 2021-01-06 Jnc株式会社 重合性液晶化合物、重合性液晶組成物および液晶重合膜
JP2021517142A (ja) 2018-03-15 2021-07-15 アクザム ソシエタ ペル アチオニ 置換ピラゾールｆｆａ４／ｇｐｒ１２０受容体作動薬
CN118040044B (zh) * 2023-11-07 2024-09-13 南昌大学 一种电解液与锂离子电池

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080537A1 (en) * 2008-12-18 2010-07-15 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
CN102186825A (zh) * 2008-10-21 2011-09-14 麦它波莱克斯股份有限公司 芳基gpr120受体激动剂和其用途
CN105209446A (zh) * 2013-03-14 2015-12-30 詹森药业有限公司 用于治疗ii型糖尿病的gpr120激动剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011255A1 (en) * 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Peroxisome proliferator-activated receptor controllers
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
GB0405033D0 (en) * 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186825A (zh) * 2008-10-21 2011-09-14 麦它波莱克斯股份有限公司 芳基gpr120受体激动剂和其用途
WO2010080537A1 (en) * 2008-12-18 2010-07-15 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
CN105209446A (zh) * 2013-03-14 2015-12-30 詹森药业有限公司 用于治疗ii型糖尿病的gpr120激动剂

Also Published As

Publication number Publication date
ES2887011T3 (es) 2021-12-21
EP3409671B1 (en) 2021-07-21
JP6303031B2 (ja) 2018-03-28
MX2016011630A (es) 2016-11-29
JP2017507189A (ja) 2017-03-16
EP3114123B1 (en) 2018-04-25
AU2014385276A1 (en) 2016-09-01
EP3409671A1 (en) 2018-12-05
CA2941445A1 (en) 2015-09-11
ES2673578T3 (es) 2018-06-22
WO2015134039A1 (en) 2015-09-11
EP3114123A1 (en) 2017-01-11
MX367852B (es) 2019-09-09
CN106414434A (zh) 2017-02-15
AU2014385276B2 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
CN105209446A (zh) 用于治疗ii型糖尿病的gpr120激动剂
TWI359148B (https=)
EP2215049B1 (en) P2x3, receptor antagonists for treatment of pain
JP5259592B2 (ja) Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体
JP7170996B2 (ja) スルホンアミド誘導体またはその薬学的に許容される酸付加塩
TWI686386B (zh) 1,3-二取代烯酮類化合物及其應用
TW200400183A (en) 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
CN109996797A (zh) 作为乳酸脱氢酶的抑制剂的1h-吡唑-1-基-噻唑及其使用方法
CN106414434B (zh) 异噻唑衍生物作为用于治疗ii型糖尿病的gpr120激动剂
JP2023516714A (ja) 新規ｅｐ４拮抗薬の合成及びその癌及び炎症における使用
US9067898B1 (en) Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes
CN105209444B (zh) 可用作gpr120的激动剂的苯并稠合杂环衍生物
HK1233634B (zh) 异噻唑衍生物作为用於治疗ii型糖尿病的gpr120激动剂
HK1233634A1 (en) Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes
JP2002506851A (ja) カルボン酸類およびアシルスルホンアミド類、そのような化合物を含む組成物ならびに治療方法
CN106061943A (zh) 可用作gpr120的激动剂的双环吡咯类衍生物
KR20080032155A (ko) 페록시좀 증식제 활성화 수용체 δ 의 활성화제
CN107162913A (zh) 一类新型氘代苯丙酸衍生物、其制备方法及其作为药物的用途
WO2025209499A1 (zh) Polθ抑制剂及其药物组合物和应用
HK40005165A (en) Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes
HK40005165B (en) Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1233634

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20191231